🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Patients w/ relapsed/refractory follicular #lymphoma reported consistent or increased response rates, survival benefits, & health-related quality of life when taking some form of #epcoritamab, according to 3 posters presented at #EHA2025. Learn more: hubs.li/Q03rQLpm0

Two posters presented at the 2025 European Hematology Association Congress (#EHA2025) support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed #multiplemyeloma: hubs.li/Q03rRz_D0

In part 2 of our interview with Dr Ola Landgren ahead of #EHA2025, he shares ADVANCE trial results, which show that adding #daratumumab to carfilzomib-lenalidomide-dexamethasone mproves outcomes in newly diagnosed #multiplemyeloma. Watch here: bit.ly/4mZ9nPh

#Revumenib shows promise for high-risk patients with acute myeloid leukemia (#AML) with specific genetic mutations, demonstrating efficacy with no new safety signals, according to data in posters presented at #EHA2025. Learn more here: hubs.li/Q03r-MRX0

Merlin Engelke, MS, explains at #EHA2025 that an #AI-driven machine learning model was refined & validated to accurately classify acute #leukemia subtypes from routine laboratory data, offering a potential tool for improving diagnosis worldwide. Tune in: bit.ly/4dXA9TY

At #EHA2025, Dr Adela Perolla told #AJMC that #burnout is rising sharply in #hematology due to emotional strain, long hours, and high patient demands, impacting both physician well-being and patient care. Watch here: bit.ly/3SRvR74

Abstracts presented during the plenary session of #EHA2025 spanned from novel drug regimens for #myeloma and #lymphoma to investigation of leukemias on the molecular and genetic levels. Learn more here: hubs.li/Q03s7Cqk0

The late-breaking abstracts presented on the last day of #EHA2025 show “what a vibrant clinical specialty we’re in,” according to session cochair Brian Huntly, PhD. Learn more here: hubs.li/Q03s7F6n0

Adolescent and young adult patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients at #EHA2025 agreed. Learn more: hubs.li/Q03s7Gbt0

What are the clinical implications of 5-year CheckMate 9LA results in metastatic #NSCLC? Experts discuss long-term impact of nivolumab + ipilimumab + chemo vs chemo alone, key insights, and evolving treatment strategies. Get the #ClinicalPerspectives: hubs.li/Q03s0h5d0

How are bispecific and trispecific antibodies transforming myeloma care? Our new AJMC video from ASCO 2025 breaks it down. Plus, insights from MDA 2025 and how tech could ease rural staffing gaps. In the meantime, stay up to date: hubs.li/Q03scT7n0 #oncology #healthcare

#Trastuzumabderuxtecan (T-Dxd) is highly effective in HER2+ #breastcancer—but interstitial lung disease #ILD risk remains a serious concern, new research presented at #ASCO2025 finds. Read more: hubs.li/Q03sbCZk0

In this interview, @LornaWarick, CEO of the Lymphoma Coalition / Lymphoma Coalition, discusses the adverse effects experienced by patients with #lymphoma and #chroniclymphocyticleukemia, and how it impacts their well-being if left unaddressed. Watch now! hubs.li/Q03sbGVQ0

The FDA granted approval to CSL’s garadacimab-gxii (Andembry), a first-in-class factor XII (FXIIa) inhibitor for patients with hereditary angioedema (HAE). Read more! hubs.li/Q03srxd60

At the 30th European Hematology Association (#EHA2025) Congress, #hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide. Watch our recap! hubs.li/Q03sryKd0

SPONSORED: Deepen your understanding of elevated Lp(a) levels with AJMC's new Interactive Tool. Access expert insights and comprehensive academic resources all in one place. Explore now: hubs.li/Q03sdbxM0

Sharon Walmsley, CM, MD, FRCPC, discusses long-acting cabotegravir + rilpivirine in the real world: 95% viral suppression in #OPERA cohort, but only 62% received injections on time. Adherence remains a key challenge. Watch: hubs.li/Q03swJqr0

Republicans have introduced the #ChooseMedicareAct, a bill that would create a Medicare “Part E,” giving individuals and employers the option to buy into Medicare through ACA marketplaces. Learn more: hubs.li/Q03sD_yK0

Diagnosis of #IPF and #PPF is often delayed due to vague symptoms and misattribution. Greater clinician awareness, timely referrals, and interdisciplinary collaboration are key to improving care and reducing burden. Learn More With This #AJMCPeerExchange: hubs.li/Q03sMK2m0

On this #Juneteenth and #WorldSickleCellDay, we recognize the legacy of health disparities—and the hope brought by progress. New gene therapies are changing the future of sickle cell disease, but access and equity must follow. Learn more: hubs.li/Q03sXb2P0